Cadrenal Therapeutics (CVKD) announced a leadership transition appointing James Ferguson as its new chief medical officer, effective immediately. Ferguson will lead the late-stage clinical ...

Raymond James analyst Steven Seedhouse raised the firm’s price target on Viking Therapeutics (VKTX) to $125 from $122 and keeps a Strong Buy rating on the shares. The firm notes that the two ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 poised to be another pivotal year for Gain ...

Wedbush analyst David Nierengarten last night initiated coverage of Bicara Therapeutics (BCAX) with an Outperform rating and $31 price target The firm views the shares as an opportunity to own a ...

Feb. 05, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of ...

Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on VKTX: Viking Therapeutics NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

Analysing the top 10 tech company logos, we can understand the art and science behind creating visual identities that stand out from the crowd. Most people scroll past logos like they're invisible.

Pre-earnings options volume in Viking Therapeutics (VKTX) is normal with calls leading puts 15:2. Implied volatility suggests the market is anticipating a move near 8.9%, or $2.95, after results ...

10:01 EST Transcode Therapeutics (RNAZ) Inc trading resumes Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment ...

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $460 from $475 and keeps a Buy rating on the shares. United Therapeutics is the firm’s top pick in Specialty Pharma in 2025 ...

BioXcel Therapeutics (BTAI) provided an update on the progress of its late-stage clinical programs for lead neuroscience asset BXCL501, as well as its recent steps to enhance operational and ...

TD Cowen initiated coverage of Palvella Therapeutics (PVLA) with a Buy rating and $44 price target The firm thinks Palvella’s “promising” Qtorin formulation platform will likely generate ...